Motilal Oswal initiates coverage on Mankind Pharma with buy rating, sees an upside of 20%

Motilal Oswal recommended a ‘buy’ rating with a target price of 2,650, sees an upside potential of 20 per cent.

Vaamanaa Sethi
Published13 Jun 2024, 06:59 PM IST
Motilal Oswal intiates coverage on Mankind Pharma recommending a buy rating
Motilal Oswal intiates coverage on Mankind Pharma recommending a buy rating(REUTERS)

Domestic brokerage firm Motilal Oswal has initiated coverage on Mankind Pharma, citing its robust brand visibility, sustainable earnings growth, and superior return ratios. 

The brokerage firm has recommended a ‘buy’ rating with a target price of 2,650, sees an upside potential of 20 per cent.

“Accordingly, we expect a 16% earnings CAGR for MANKIND over FY24-27. Considering its strong brand visibility, sustainable earning growth and superior return ratios, we value MANKIND at 40x12M forward earnings (30% premium to the Healthcare sector PE) to arrive at a TP of INR 2,650,” the firm said in its note.

Also read: Ambuja Cements' acquisition of Penna Cement for 10,422 crore raises Adani's cement market share by 8%

Considering the company's broadened product range across key therapies, a growing focus on chronic treatments, expansion of its brand portfolio, enhanced productivity of medical representatives, and increased presence in metro and Tier-I cities, the domestic brokerage has applied a 40x multiple on projected earnings for the next 12 months. This valuation reflects a 30% premium compared to the pharmaceutical sector's current valuation.

The firm noted that Mankind Pharma has implemented a disruptive strategy to build its DF business, focusing on engaging customers and influencers in tier II and lower cities. This approach has propelled the company to the forefront of the industry in terms of prescription volume.

“Mankind Pharma is working on multiple levers to boost growth over the next three to five years: a) increasing the scope of business in chronic therapies (36% of DF sales in FY24) by expanding niche products in portfolio, b) enhancing its presence in metro/Tier-I cities (53% of DF sales in FY24), and c) investing aggressively in brand building in the prescription and consumer healthcare segments,” the firm added.

Also read: L&T Finance shares rise over 5% to reach all-time high; what's driving the rally?

Mankind has shown significant outperformance in respiratory therapies, achieving an 11% sales compound annual growth rate (CAGR) compared to the industry's 10% CAGR over MAT Apr '20-24. Its leading products in this category include cough preparations and bronchodilator inhalant preparations.

However, Motilal Oswal pointed out that lower-than-expected growth in the dermatophytosis (DF) segment, subdued export demand, and decreased medical representative productivity pose key risks to the company's ratings.

 

Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.MoreLess

News in Numbers

Numbers that help you understand news better
₹68,885 Cr

3.15L

48%

₹6.7 T

$240.5 M

$459 M

$3 B

₹588.25 Cr

₹20,000 Cr

7.93 Cr

₹8,943 Cr

10%

20 Yrs

First Published:13 Jun 2024, 06:59 PM IST
HomeMarketsStock MarketsMotilal Oswal initiates coverage on Mankind Pharma with buy rating, sees an upside of 20%

Most Active Stocks

Bharat Electronics

313.50
03:59 PM | 18 JUL 2024
-12.85 (-3.94%)

Oil & Natural Gas Corporation

331.20
03:59 PM | 18 JUL 2024
8.8 (2.73%)

Zee Entertainment Enterprises

142.45
03:59 PM | 18 JUL 2024
-13 (-8.36%)

Tata Steel

166.35
03:56 PM | 18 JUL 2024
-0.7 (-0.42%)
More Active Stocks

Market Snapshot

  • Top Gainers
  • Top Losers
  • 52 Week High

India Cements

344.75
03:54 PM | 18 JUL 2024
21.7 (6.72%)

IDBI Bank

92.19
03:59 PM | 18 JUL 2024
4.27 (4.86%)

Endurance Technologies

2,679.00
03:29 PM | 18 JUL 2024
102.4 (3.97%)

Gillette India

8,002.75
03:29 PM | 18 JUL 2024
275 (3.56%)
More from Top Gainers

Recommended For You

    More Recommendations

    Gold Prices

    • 24K
    • 22K
    Bangalore
    75,099.00-147.00
    Chennai
    74,659.00-440.00
    Delhi
    74,512.00-294.00
    Kolkata
    75,539.0073.00

    Fuel Price

    • Petrol
    • Diesel
    Bangalore
    102.86/L0.00
    Chennai
    100.76/L0.00
    Kolkata
    104.95/L0.00
    New Delhi
    94.72/L0.00
    OPEN IN APP
    HomeMarketsPremiumInstant LoanBudget